The Drug-Induced Respiratory Disease Website and App

XLV. Pleural and/or pericardial involvement

XLV.e Hemothorax - Serosanguineous pleural effusion

XLV. Pleural and/or pericardial involvement

XLV.f Pneumothorax

XLV. Pleural and/or pericardial involvement

XLV.h Chylothorax

XLV. Pleural and/or pericardial involvement

XLV.n Hemopericardium - Bloody pericardial effusion

XLV. Pleural and/or pericardial involvement

XLV.z Bilateral tension pneumothorax (can be fatal)

XLV. Pleural and/or pericardial involvement

XLV.ac Pneumothorax, bilateral

XLVI. Pulmonary vasculopathy

XLVI.q Septic pulmonary embolism

LI. Cardiovascular involvement / toxicity

LI.c Pericardial effusion (w/wo tamponade)

LI. Cardiovascular involvement / toxicity

LI.aa Pneumopericardium

LI. Cardiovascular involvement / toxicity

LI.ag Aortic dissection

LI. Cardiovascular involvement / toxicity

LI.ao Cardiac injury/trauma

LI. Cardiovascular involvement / toxicity

LI.av Aortitis

LI. Cardiovascular involvement / toxicity

LI.ax Infectious aortitis

LI. Cardiovascular involvement / toxicity

LI.bh Septic/purulent pericardial effusion

LIX. Infections & related conditions

LIX.an Purulent pericardial effusion

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.o Pulmonary alveolar proteinosis (PAP)

I. Interstitial/parenchymal lung disease

I.z Progression, acceleration or exacerbation of preexisting ILD/fibrosis

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.a Pulmonary edema, noncardiogenic (NCPE)

XLV. Pleural and/or pericardial involvement

XLV.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

XLV. Pleural and/or pericardial involvement

XLV.c Pleural thickening - Fibrothorax

XLV. Pleural and/or pericardial involvement

XLV.d Pleural/pericardial effusion, ANA positive (DI lupus)

XLV. Pleural and/or pericardial involvement

XLV.h Chylothorax

XLV. Pleural and/or pericardial involvement

XLV.i Pleuritis (can cause chest pain)

XLV. Pleural and/or pericardial involvement

XLV.m Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

XLVI. Pulmonary vasculopathy

XLVI.b Pulmonary arterial hypertension

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.d Lupus - Lupus syndrome (see also Vd)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.t Fluid retention

L. Miscellaneous

L.b Chest pain (acute or subacute), lone or prominent

LI. Cardiovascular involvement / toxicity

LI.c Pericardial effusion (w/wo tamponade)

LV. Imaging

LV.m Imaging: Interlobular septal thickening

LV. Imaging

LV.ap Imaging: Pleural effusion

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.a BAL: An excess proportion of lymphocytes

LVIII. Pathology

LVIII.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

LVIII. Pathology

LVIII.n Path: Pulmonary alveolar proteinosis pattern (PAP pattern)

LVIII. Pathology

LVIII.bm Path: Pleuritis, pleural fibrosis

LVIII. Pathology

LVIII.bp Path: Organizing fibrinous pleuritis (OFP)

XLV. Pleural and/or pericardial involvement

XLV.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

XLV. Pleural and/or pericardial involvement

XLV.c Pleural thickening - Fibrothorax

XLV. Pleural and/or pericardial involvement

XLV.h Chylothorax

XLV. Pleural and/or pericardial involvement

XLV.o The 'folded lung' (Blesovsky syndrome)

LI. Cardiovascular involvement / toxicity

LI.b Valvular heart disease and/or dysfunction

LI. Cardiovascular involvement / toxicity

LI.l Constrictive pericarditis - Pericardial thickening

LV. Imaging

LV.ap Imaging: Pleural effusion

LV. Imaging

LV.ar Imaging: Pleural thickening w/wo rounded atelectasis

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.al Pleuropneumonitis

XLIII. Airway involvement

XLIII.a Bronchospasm - Wheezing - Asthma

XLV. Pleural and/or pericardial involvement

XLV.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

XLV. Pleural and/or pericardial involvement

XLV.c Pleural thickening - Fibrothorax

XLV. Pleural and/or pericardial involvement

XLV.h Chylothorax

XLV. Pleural and/or pericardial involvement

XLV.m Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

XLV. Pleural and/or pericardial involvement

XLV.o The 'folded lung' (Blesovsky syndrome)

XLVII. Mediastinal involvement

XLVII.d Fibrosing mediastinitis

L. Miscellaneous

L.r Chest pressure/discomfort

L. Miscellaneous

L.an Retroperitoneal fibrosis

LI. Cardiovascular involvement / toxicity

LI.a Left or biventricular dysfunction/failure

LI. Cardiovascular involvement / toxicity

LI.b Valvular heart disease and/or dysfunction

LI. Cardiovascular involvement / toxicity

LI.c Pericardial effusion (w/wo tamponade)

LI. Cardiovascular involvement / toxicity

LI.h Coronary artery disease (acute) - Myocardial ischemia/infarction

LV. Imaging

LV.ap Imaging: Pleural effusion

LV. Imaging

LV.ar Imaging: Pleural thickening w/wo rounded atelectasis

LVIII. Pathology

LVIII.bm Path: Pleuritis, pleural fibrosis

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.w Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

I. Interstitial/parenchymal lung disease

I.z Progression, acceleration or exacerbation of preexisting ILD/fibrosis

I. Interstitial/parenchymal lung disease

I.ac Radiation-induced lung injury (RILI)

I. Interstitial/parenchymal lung disease

I.ad Acute radiation pneumonitis

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.e ARDS - Acute lung injury

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.c Upper airway obstruction other than angioedema or hematoma

XLV. Pleural and/or pericardial involvement

XLV.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

XLV. Pleural and/or pericardial involvement

XLV.h Chylothorax

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.h Dyspnea, unexplained otherwise

L. Miscellaneous

L.t Cavitation/necrosis of lung tumor or metastases

LI. Cardiovascular involvement / toxicity

LI.l Constrictive pericarditis - Pericardial thickening

LV. Imaging

LV.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

LV. Imaging

LV.bp Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.a BAL: An excess proportion of lymphocytes

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.c BAL: An excess proportion of eosinophils

LVIII. Pathology

LVIII.a Path: NSIP-cellular pattern (see also Ia, Ib)

LVIII. Pathology

LVIII.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

LVIII. Pathology

LVIII.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

LVIII. Pathology

LVIII.e Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

LVIII. Pathology

LVIII.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

LVIII. Pathology

LVIII.q Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)

LVIII. Pathology

LVIII.v Path: NSIP-fibrotic pattern

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.i Subclinical pulmonary infiltrates/ILD

I. Interstitial/parenchymal lung disease

I.p Focal/localized area of pneumonitis/fibrosis

I. Interstitial/parenchymal lung disease

I.w Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

I. Interstitial/parenchymal lung disease

I.y Pleuroparenchymal fibroelastosis (PPFE)

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.e ARDS - Acute lung injury

XLII. Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.c Hemoptysis

XLIII. Airway involvement

XLIII.j Bronchiectasis

XLIII. Airway involvement

XLIII.ai Bronchial stenosis/stricture

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.c Upper airway obstruction other than angioedema or hematoma

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.d Laryngeal disorder-Laryngeal nerve palsy (dysphonia, hoarseness)

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.g Vocal cord paresis/paralysis

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.s Tracheal/large airway necrosis, chondronecrosis, perforation

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.aa Pseudomembranous tracheitis/tracheobronchitis

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.ab Airway (e.g. tracheoesophageal) fistula

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.ac Large airway necrosis

XLV. Pleural and/or pericardial involvement

XLV.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

XLV. Pleural and/or pericardial involvement

XLV.b Eosinophilic pleural effusion

XLV. Pleural and/or pericardial involvement

XLV.c Pleural thickening - Fibrothorax

XLV. Pleural and/or pericardial involvement

XLV.f Pneumothorax

XLV. Pleural and/or pericardial involvement

XLV.h Chylothorax

XLV. Pleural and/or pericardial involvement

XLV.l Malignant pleural mesothelioma

XLV. Pleural and/or pericardial involvement

XLV.m Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

XLV. Pleural and/or pericardial involvement

XLV.u The apical cap

XLVI. Pulmonary vasculopathy

XLVI.c Pulmonary veno-occlusive disease

XLVI. Pulmonary vasculopathy

XLVI.r Pulmonary artery aneurysm(s)

XLVI. Pulmonary vasculopathy

XLVI.aa Pulmonary artery stenosis

XLVII. Mediastinal involvement

XLVII.d Fibrosing mediastinitis

XLVII. Mediastinal involvement

XLVII.i Mediastinitis

XLVII. Mediastinal involvement

XLVII.j Compression of mediastinal structures/organs

XLVII. Mediastinal involvement

XLVII.l Calcification of mediastinal lymph nodes

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.a Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.aj Paraspinal muscle myositis/myopathy/neuromyopathy +- the dropped head syndrome

L. Miscellaneous

L.h Aspiration, aspiration pneumonia (w/wo demonstrable pharyngeal dysmotility)

L. Miscellaneous

L.m Chest deformity: platythorax

L. Miscellaneous

L.s Rib fracture

L. Miscellaneous

L.ad Vertebral compression fracture

L. Miscellaneous

L.bc Aorto-esophageal fistula

L. Miscellaneous

L.bn Dropped-head syndrome

LI. Cardiovascular involvement / toxicity

LI.a Left or biventricular dysfunction/failure

LI. Cardiovascular involvement / toxicity

LI.b Valvular heart disease and/or dysfunction

LI. Cardiovascular involvement / toxicity

LI.g Cardiomyopathy (acute, subacute, chronic)

LI. Cardiovascular involvement / toxicity

LI.h Coronary artery disease (acute) - Myocardial ischemia/infarction

LI. Cardiovascular involvement / toxicity

LI.l Constrictive pericarditis - Pericardial thickening

LI. Cardiovascular involvement / toxicity

LI.p Coronary artery disease (subacute, chronic)

LI. Cardiovascular involvement / toxicity

LI.t Heart block (bundle branch- or AV-)

LI. Cardiovascular involvement / toxicity

LI.af Effusive-constrictive pericarditis

LI. Cardiovascular involvement / toxicity

LI.am Late left ventricular dysfunction/failure

LI. Cardiovascular involvement / toxicity

LI.ap Pericardial calcification

LI. Cardiovascular involvement / toxicity

LI.bf Coarctation of the aorta (acquired)

LI. Cardiovascular involvement / toxicity

LI.bx Aortoesophageal fistula

LII. Esophageal involvement

LII.b Esophageal pathology (erosion, ulcer, tear, rupture, fistula)

LII. Esophageal involvement

LII.c Esophageal stenosis/stricture

LII. Esophageal involvement

LII.d Esophageal toxicity

LV. Imaging

LV.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

LV. Imaging

LV.bm Imaging: Hyperlucent lung

LV. Imaging

LV.bn Imaging: Atelectasis (a combination of increased density and volume loss. Typically lobar)

LV. Imaging

LV.bp Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan

LVIII. Pathology

LVIII.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

LVIII. Pathology

LVIII.x Path: Pulmonary fibrosis (not otherwise specified or unclassifiable)

LX. Neoplastic conditions

LX.a Lung cancer

LX. Neoplastic conditions

LX.d Malignant mesothelioma (pleural, pericardial)

LX. Neoplastic conditions

LX.e Breast cancer

LX. Neoplastic conditions

LX.j Pulmonary synovial sarcoma

LX. Neoplastic conditions

LX.l Chondrosarcoma

LX. Neoplastic conditions

LX.m Tumor of the heart

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.i Subclinical pulmonary infiltrates/ILD

I. Interstitial/parenchymal lung disease

I.l Lung nodule or nodules

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.p Focal/localized area of pneumonitis/fibrosis

I. Interstitial/parenchymal lung disease

I.w Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

I. Interstitial/parenchymal lung disease

I.y Pleuroparenchymal fibroelastosis (PPFE)

I. Interstitial/parenchymal lung disease

I.z Progression, acceleration or exacerbation of preexisting ILD/fibrosis

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.e ARDS - Acute lung injury

XLII. Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.h Major/massive hemoptysis

XLIII. Airway involvement

XLIII.ai Bronchial stenosis/stricture

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.c Upper airway obstruction other than angioedema or hematoma

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.g Vocal cord paresis/paralysis

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.s Tracheal/large airway necrosis, chondronecrosis, perforation

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.ab Airway (e.g. tracheoesophageal) fistula

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.ac Large airway necrosis

XLV. Pleural and/or pericardial involvement

XLV.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

XLV. Pleural and/or pericardial involvement

XLV.c Pleural thickening - Fibrothorax

XLV. Pleural and/or pericardial involvement

XLV.f Pneumothorax

XLV. Pleural and/or pericardial involvement

XLV.h Chylothorax

XLV. Pleural and/or pericardial involvement

XLV.k Pleural calcifications

XLVI. Pulmonary vasculopathy

XLVI.c Pulmonary veno-occlusive disease

XLVI. Pulmonary vasculopathy

XLVI.w Pulmonary lymphangiectasis

XLVII. Mediastinal involvement

XLVII.d Fibrosing mediastinitis

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.j Phrenic nerve injury - Hemi- or bilateral diaphragmatic paralysis

L. Miscellaneous

L.b Chest pain (acute or subacute), lone or prominent

L. Miscellaneous

L.t Cavitation/necrosis of lung tumor or metastases

L. Miscellaneous

L.ad Vertebral compression fracture

LI. Cardiovascular involvement / toxicity

LI.b Valvular heart disease and/or dysfunction

LI. Cardiovascular involvement / toxicity

LI.l Constrictive pericarditis - Pericardial thickening

LI. Cardiovascular involvement / toxicity

LI.p Coronary artery disease (subacute, chronic)

LI. Cardiovascular involvement / toxicity

LI.t Heart block (bundle branch- or AV-)

LII. Esophageal involvement

LII.b Esophageal pathology (erosion, ulcer, tear, rupture, fistula)

LII. Esophageal involvement

LII.d Esophageal toxicity

LII. Esophageal involvement

LII.e Esophageal dysmotility

LV. Imaging

LV.bp Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.a BAL: An excess proportion of lymphocytes

LVIII. Pathology

LVIII.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

LVIII. Pathology

LVIII.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

LVIII. Pathology

LVIII.q Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)

LVIII. Pathology

LVIII.v Path: NSIP-fibrotic pattern

LVIII. Pathology

LVIII.cg Path: Diffuse lymphangiectasis

LIX. Infections & related conditions

LIX.e Pneumocystis jiroveci pneumonia

LIX. Infections & related conditions

LIX.ae Reactivation of a prior pulmonary infection (TB, melioidosis)

LX. Neoplastic conditions

LX.e Breast cancer

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.y Pleuroparenchymal fibroelastosis (PPFE)

XLV. Pleural and/or pericardial involvement

XLV.b Eosinophilic pleural effusion

XLV. Pleural and/or pericardial involvement

XLV.d Pleural/pericardial effusion, ANA positive (DI lupus)

XLV. Pleural and/or pericardial involvement

XLV.h Chylothorax

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.a Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.d Lupus - Lupus syndrome (see also Vd)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.l Myopathy-Myositis-Polymyositis (see also under Xba)

L. Miscellaneous

L.b Chest pain (acute or subacute), lone or prominent

LVIII. Pathology

LVIII.a Path: NSIP-cellular pattern (see also Ia, Ib)

LVIII. Pathology

LVIII.aa Path: Endogenous lipoid pneumonia (phospholipidosis)

LVIII. Pathology

LVIII.br Path: Pleuroparenchymal fibrosis/fibroelastosis (PPFE)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.v Relapsing or migrating pneumonitis/pneumonia (see also Id)

I. Interstitial/parenchymal lung disease

I.y Pleuroparenchymal fibroelastosis (PPFE)

I. Interstitial/parenchymal lung disease

I.ar Interstitial Pneumonitis with Autoimmune Features (IPAF)

I. Interstitial/parenchymal lung disease

I.as The association of ILD and myositis

XLIII. Airway involvement

XLIII.ab Cough (lone)

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.a Angioedema (may cause UAO, asphyxia and death)

XLV. Pleural and/or pericardial involvement

XLV.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

XLV. Pleural and/or pericardial involvement

XLV.b Eosinophilic pleural effusion

XLV. Pleural and/or pericardial involvement

XLV.d Pleural/pericardial effusion, ANA positive (DI lupus)

XLV. Pleural and/or pericardial involvement

XLV.h Chylothorax

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.a Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.ac Myositis of the respiratory muscles (May lead to respiratory muscle paralysis)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.d Lupus - Lupus syndrome (see also Vd)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.l Myopathy-Myositis-Polymyositis (see also under Xba)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.bb Rhabdomyolysis (see also under Xj)

L. Miscellaneous

L.b Chest pain (acute or subacute), lone or prominent

LI. Cardiovascular involvement / toxicity

LI.ad Pericardial fat necrosis

LV. Imaging

LV.x Imaging: Waxing and waning nodules

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.f BAL: Foamy macrophages

LVIII. Pathology

LVIII.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

LVIII. Pathology

LVIII.e Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

LVIII. Pathology

LVIII.v Path: NSIP-fibrotic pattern

LVIII. Pathology

LVIII.aa Path: Endogenous lipoid pneumonia (phospholipidosis)

LVIII. Pathology

LVIII.ae Path: Foamy inclusions in alveolar macrophages and/or in other lung cells

LVIII. Pathology

LVIII.br Path: Pleuroparenchymal fibrosis/fibroelastosis (PPFE)

I. Interstitial/parenchymal lung disease

I.z Progression, acceleration or exacerbation of preexisting ILD/fibrosis

XLV. Pleural and/or pericardial involvement

XLV.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

XLV. Pleural and/or pericardial involvement

XLV.c Pleural thickening - Fibrothorax

XLV. Pleural and/or pericardial involvement

XLV.f Pneumothorax

XLV. Pleural and/or pericardial involvement

XLV.h Chylothorax

XLVII. Mediastinal involvement

XLVII.i Mediastinitis

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.m Sarcoid-like granulomatosis (endo-/extrathoracic)

LI. Cardiovascular involvement / toxicity

LI.l Constrictive pericarditis - Pericardial thickening

LVI. Distinctive patterns - 'Eye-catchers'

LVI.e Eye-catcher: Multiple radiolucent balls